Evaxion A/S (EVAX) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evaxion A/S (EVAX) has outperformed Scilex (SCLX) over the past year, losing 51.5% versus a loss of 73.0%. Over five years, SCLX leads with a -98.6% price change compared with -99.2% for EVAX. Evaxion A/S is the larger company by market cap ($27.5 million vs $20.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | SCLX |
|---|---|---|
| Share price | $3.05 | $2.96 |
| Market cap | $27.52M | $20.82M |
| 1-day change | -2.87% | -15.19% |
| YTD return | -36.06% | -61.03% |
| 1-year return | -51.51% | -72.96% |
| 5-year return | -99.23% | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-1.00 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $16.81 |
| 52-week low | $2.77 | $2.62 |
| Distance from 52-week high | -74.90% | -82.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +268.85% | — |
| Average volume | 199.49K | 53.62K |
| Shares outstanding | 9.02M | 7.03M |
| Employees | 46 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVAX has outperformed SCLX by 21.4 percentage points over the past year.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Healthcare · Drug Manufacturers - General · 34 employees
EVAX vs SCLX FAQ
Which is bigger, Evaxion A/S or Scilex?
Evaxion A/S (EVAX) is larger, with a market capitalization of $27.52M compared with $20.82M for Scilex (SCLX).
Which stock has performed better over the past year, EVAX or SCLX?
EVAX returned -51.51% over the past 12 months, compared with -72.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and Scilex in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Evaxion A/S and Drug Manufacturers - General for Scilex.